M&A / Deals Bayer looks to uphold Eylea legacy with $2.45bn Perfuse buyout Pharmaceutical TechnologyIf approved, Perfuse's PER-001 could continue Bayer's ophthalmology legacy defined by blockbuster retinal disease therapy, Eylea.OphthalmologyRead full story pharminent May 6, 2026 (Last updated: May 6, 2026) Pharmaceutical Technology If approved, Perfuse’s PER-001 could continue Bayer’s ophthalmology legacy defined by blockbuster retinal disease therapy, Eylea. Ophthalmology Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Lilly inflates US facility investment spending by $4.5bnNext: Novo hikes guidance on Wegovy pill’s fast sales start Related Stories M&A / Deals AbbVie climbs post-Allergan M&A peak with Apogee buy pharminent June 22, 2026 M&A / Deals Lilly bets up to $800M for BioArctic’s brain delivery tech pharminent June 22, 2026 M&A / Deals Insilico and SK Bio forge $2.5bn AI neuroimmunity alliance pharminent June 22, 2026
